These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 14737123)

  • 1. The 14-3-3 cancer connection.
    Hermeking H
    Nat Rev Cancer; 2003 Dec; 3(12):931-43. PubMed ID: 14737123
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advances in studies on inhibitor of apoptosis proteins and cancer therapy].
    Wang XH; Fu LW
    Yao Xue Xue Bao; 2006 Feb; 41(2):103-7. PubMed ID: 16671537
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-apoptotic proteins-targets for chemosensitization of tumor cells and cancer treatment.
    Kostanová-Poliaková D; Sabová L
    Neoplasma; 2005; 52(6):441-9. PubMed ID: 16284687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bibliography. Current world literature. Therapeutic modalities.
    Curr Opin Oncol; 2000 Nov; 12(6):B238-43. PubMed ID: 11085462
    [No Abstract]   [Full Text] [Related]  

  • 6. Bibliography. Current world literature. Therapeutic modalities.
    Curr Opin Oncol; 2001 Nov; 13(6):B172-92. PubMed ID: 11708263
    [No Abstract]   [Full Text] [Related]  

  • 7. [The inhibition of apoptosis in cancer cells resistant to anticancer drugs].
    Nowak R; Tarasiuk J
    Postepy Biochem; 2004; 50(4):330-43. PubMed ID: 15957528
    [No Abstract]   [Full Text] [Related]  

  • 8. Introduction to resistance to anticancer agents.
    Kruh GD
    Oncogene; 2003 Oct; 22(47):7262-4. PubMed ID: 14576836
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of apoptosis signaling for cancer therapy.
    Fulda S; Debatin KM
    Arch Immunol Ther Exp (Warsz); 2006; 54(3):173-5. PubMed ID: 16652217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ending the prolonged life of cancer cells.
    Wagner G
    Nat Chem Biol; 2005 Jun; 1(1):8-9. PubMed ID: 16407985
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of proteasome inhibitor action and resistance in cancer.
    McConkey DJ; Zhu K
    Drug Resist Updat; 2008; 11(4-5):164-79. PubMed ID: 18818117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis signaling in tumor therapy.
    Fulda S; Debatin KM
    Ann N Y Acad Sci; 2004 Dec; 1028():150-6. PubMed ID: 15650241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial function as an emerging 'target of interest' for cancer treatment.
    Sausville EA
    Curr Opin Investig Drugs; 2009 Jun; 10(6):523-5. PubMed ID: 19513940
    [No Abstract]   [Full Text] [Related]  

  • 16. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.
    Hu X; Xuan Y
    Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the unfolded protein response in tumour development: friend or foe?
    Ma Y; Hendershot LM
    Nat Rev Cancer; 2004 Dec; 4(12):966-77. PubMed ID: 15573118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor progression--targets for differential therapy.
    Pardee AB
    J Cell Physiol; 2006 Dec; 209(3):589-91. PubMed ID: 17001691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic implications of the new biology.
    DeVita VT; Abou-Alfa GK
    Cancer J; 2000 Apr; 6 Suppl 2():S113-20. PubMed ID: 10803824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.